Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergent Respiratory LLC

www.eresp.com

Latest From Pronova BioPharma ASA

Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims

The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.

Consumer Regulation

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials

The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.

Clinical Trials Research and Development Strategies

GSK's Lovaza faces generics after court invalidates Pronova patent

GlaxoSmithKline's omega-3 fatty acid Lovaza and Amarin's Vascepa for the treatment of high triglycerides may face generic competition within the next few months after a US appeals court invalidated the last Pronova BioPharma patent protecting GSK's fish oil pill.

ANCHOR Indication For Amarin’s Vascepa Will Face FDA Panel Scrutiny

Key question at the Oct. 16 advisory committee review could be whether FDA should wait for results from an ongoing cardiovascular outcomes trial before significantly broadening the prescription fish oil product’s approval to include adults with high triglycerides and mixed dyslipidemia.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Emergent Respiratory Products Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Emergent Respiratory LLC
  • Senior Management
  • Hans Gregory Wood, Pres. & CEO
    Gary Calvaneso, VP, Sales & Mktg.
  • Contact Info
  • Emergent Respiratory LLC
    Phone: (714) 263-3777
    420 Exhange
    Ste. 250
    Irvine, CA 92602
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register